12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relistor methylnaltrexone regulatory update

Salix disclosed in its 3Q12 earnings that FDA indicated it will require "a very large, well-controlled, chronic administration trial" to assess the safety of subcutaneous Relistor methylnaltrexone prior to approval for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain. FDA communicated the request during an October end-of-review meeting with the...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >